Richard Zeifman
Assistant Professor of Psychology and Director of PATH Lab
Data updated
Research Footprint
Richard Zeifman appears in 23 tracked papers (2019–2026), most studied alongside Psilocybin, MDMA and Ayahuasca, across Depressive Disorders, Anxiety Disorders and Suicidality.
Most-cited paper: Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression (222 citations).
Frequent co-authors: Robin Carhart-Harris, Hannes Kettner and David Erritzoe.
Publication Landscape
How the 23 papers Blossom tracks for Richard Zeifman line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Richard Zeifman's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 23 of 23 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Richard Zeifman publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Richard Zeifman publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Dr. Richard Zeifman leads the PATH Lab at The New School, focusing on the safety and efficacy of psychedelic-assisted therapy. As a licensed clinical psychologist and researcher, he conducts clinical trials and effectiveness studies to understand how psilocybin and MDMA promote psychological flexibility and long-term recovery in patients with MDD, cancer-related distress, and PTSD.
Key Impact
Investigates mechanisms of change in psychedelic therapy for depression, trauma, and suicidality.
Collaboration Network
54 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Richard Zeifman's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Richard Zeifman is associated with.
The New School for Social Research
The New School for Social Research is the graduate division of The New School in New York City, offering advanced degrees and research in the social sciences, philosophy, and history. It is known for progressive, interdisciplinary scholarship and a history rooted in the University in Exile that supported scholars fleeing fascism in the 1930s.
View stakeholder →Centre for Addiction and Mental Health
hospitalThe Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health teaching hospital, located in Toronto, Ontario. CAMH is a major hub for psychedelic research in Canada, running trials on psilocybin, MDMA, and ketamine across a range of psychiatric indications.
View stakeholder →Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →Toronto Metropolitan University
academicToronto Metropolitan University (formerly Ryerson University) is a public research university in downtown Toronto, Canada. Its psychology, health science, and social science researchers participate in clinical studies on psychedelic-assisted therapy, with faculty investigating the effects of psilocybin and other compounds on mental health outcomes in clinical and community populations.
View stakeholder →